Harmaline Analogs as Substrate-Selective Cyclooxygenase-2 Inhibitors

Area of Science:

• Medicinal Chemistry
• Enzyme Inhibition
• Neuroscience

Background:

• Cyclooxygenase-2 (COX-2) plays a role in inflammation and pain.
• Endocannabinoid (EC) levels are implicated in various neurological and inflammatory conditions.
• Selective inhibition of 2-arachidonoylglycerol (2-AG) oxygenation by COX-2 is a therapeutic target.

Purpose of the Study:

• To design and synthesize harmaline analogs as selective inhibitors of COX-2.
• To evaluate the substrate selectivity of these analogs for 2-AG versus arachidonic acid (AA) oxygenation.
• To elucidate the binding mode of the lead compound within the COX-2 active site.

Main Methods:

• Synthesis of a series of harmaline analogs.
• Enzyme inhibition assays using purified cyclooxygenase-2 (COX-2).
• Determination of IC50 values for 2-AG and AA oxygenation inhibition.
• X-ray crystallography of COX-2 complexed with the lead inhibitor.

Main Results:

• A specific tricyclic harmaline analog (compound 3) demonstrated potent and selective inhibition of 2-AG oxygenation by COX-2 (IC50 = 0.022 μM) compared to AA oxygenation (>1 μM).
• Crystal structure analysis revealed compound 3 binds within the COX-2 channel, interacting with residue L531.
• The study identified a novel series of tricyclic indoles with substrate-selective COX-2 inhibitory properties.

Conclusions:

• The developed harmaline analogs represent a promising new class of substrate-selective COX-2 inhibitors.
• These compounds have the potential to modulate endocannabinoid levels.
• This research lays the groundwork for developing novel therapeutics for pain, inflammation, stress, and anxiety disorders.